{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:40:02Z","timestamp":1750538402484,"version":"3.41.0"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Based on the recent publications, including large cohort retrospective study and prospective clinical trial data, we are commenting on the optimal methods on myocardial suppression in FDG PET\/CT evaluation of patients with suspected cardiac sarcoidosis.<\/jats:p>","DOI":"10.1097\/rlu.0000000000003777","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T14:01:28Z","timestamp":1623852088000},"page":"904-905","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["What Is the Optimal Method on Myocardial Suppression in FDG PET\/CT Evaluation of Cardiac Sarcoidosis?"],"prefix":"10.1097","volume":"46","author":[{"given":"Yang","family":"Lu","sequence":"first","affiliation":[{"name":"Division of Diagnostic Imaging, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadera J.","family":"Sweiss","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Illinois College of Medicine, Chicago, IL."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Homer A.","family":"Macapinlac","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Imaging, Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,6,16]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12149-014-0806-0","article-title":"Recommendations for (18)F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology recommendations","volume":"28","year":"2014","journal-title":"Ann Nucl Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2967\/jnumed.117.196287","article-title":"Joint SNMMI-ASNC expert consensus document on the role of (18)F-FDG PET\/CT in cardiac sarcoid detection and therapy monitoring","volume":"58","year":"2017","journal-title":"J Nucl Med"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jacc.2013.09.022","article-title":"Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis","volume":"63","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jcmg.2017.04.020","article-title":"Prognostic impact of extent, severity, and heterogeneity of abnormalities on 18F-FDG PET scans for suspected cardiac sarcoidosis","volume":"11","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"bib5-20250621","first-page":"jnumed.118.221549","article-title":"Role of 18F-FDG PET\/CT in cardiac sarcoid detection and therapy monitoring: addition to the expert consensus","year":"2018","journal-title":"J Nucl Med"},{"key":"bib6-20250621","first-page":"217","article-title":"Prognostic impact of FDG-PET\/CT images in patients with suspected cardiac sarcoidosis: optimal patient preparation, not complex unconventional analytics, is key to meaningful data","volume":"12","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/RLU.0000000000001465","article-title":"Suppression of myocardial 18F-FDG uptake through prolonged high-fat, high-protein, and very-low-carbohydrate diet before FDG-PET\/CT for evaluation of patients with suspected cardiac sarcoidosis","volume":"42","year":"2017","journal-title":"Clin Nucl Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1097\/RLU.0000000000003556","article-title":"An intravenous 100-mL lipid emulsion infusion dramatically improves myocardial glucose metabolism extinction in cardiac FDG PET clinical practice","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"key":"bib9-20250621","first-page":"jnumed.121.261981","article-title":"Comparison of the effect of three different dietary modifications on myocardial suppression in 18F-FDG PET\/CT evaluation of patients for suspected cardiac sarcoidosis","year":"2021","journal-title":"J Nucl Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s12350-017-0962-4","article-title":"FDG PET-CT findings of extra-thoracic sarcoid are associated with cardiac sarcoid: a rationale for using FGD PET-CT for cardiac sarcoid evaluation","volume":"26","year":"2019","journal-title":"J Nucl Cardiol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003777","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:00:42Z","timestamp":1750536042000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000003777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,16]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000003777","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2021,6,16]]}}}